Is Endoscopic Sleeve Gastroplasty (ESG) Reversible? What the Evidence Says

Yes — endoscopic sleeve gastroplasty (ESG) is generally considered reversible, and the reason is simple anatomy: ESG shrinks the stomach by placing a row of sutures that cinch it into a narrow tube, whereas a surgical sleeve gastrectomy permanently cuts away and removes 70–80% of the stomach. Because ESG removes no tissue, the stitches can loosen or stretch over time, they can be removed endoscopically, the procedure can be redone, and — crucially — a full surgical sleeve gastrectomy or gastric bypass remains completely available later if you ever need more. That is a sharp contrast with surgery, which cannot be undone. But there is an important nuance most articles get wrong: “reversible” does not mean “temporary.” While the sutures are intact, the weight-loss effect is durable — about 13.6% total body weight loss at one year in the randomized MERIT trial^[1], 15–17% pooled^[2], and near 15.9% still holding at five years^[3]. This article explains exactly what reversibility means for ESG, how it differs from the irreversibility of surgery, and why that flexibility is one of ESG's defining advantages.

The honest summary

• ESG is reversible because it uses sutures, not excision. The gastroenterologist stitches the stomach into a tube from the inside; nothing is cut out. Sutures can loosen, stretch, be removed endoscopically, or be revised — so the stomach's original anatomy is not permanently destroyed.
• Surgery is the opposite. A sleeve gastrectomy removes 70–80% of the stomach permanently^[5]; a gastric bypass permanently reroutes the anatomy. Once tissue is gone, it is gone — these procedures are not reversible in any practical sense.
• “Reversible” does not mean “temporary.” While intact, ESG's weight loss is durable: 13.6% at one year (MERIT^[1]), 15–17% pooled^[2], and 15.9% at five years^[3]. Reversibility is about your options, not about the effect fading on its own.
• ESG preserves every future surgical option. Because no tissue is removed, a surgical sleeve or bypass remains fully available if you later need more weight loss — ESG does not burn any bridges. This is one of its biggest advantages over surgery.
• The procedure can be redone or revised. If sutures loosen and some restriction is lost, ESG can be repeated or tightened, and it can be combined with a GLP-1 — ESG plus liraglutide beat ESG alone in one randomized study (Badurdeen 2021^[4]).
• The safety profile supports this flexibility. Serious adverse events run about 2% (Hedjoudje 2020^[2]), with no procedure-related deaths in the major series^[1][3] — a favorable profile for a reversible, incisionless intervention.
• Contrast with a GLP-1's kind of “reversibility.” A GLP-1 is reversible in that you can stop the injection — but its weight loss tends to reverse too, whereas ESG's restriction and its weight-loss effect persist while the sutures hold.

Why ESG is reversible: sutures, not excision

ESG is a bariatric endoscopy procedure — done entirely through the mouth with a flexible endoscope, no incisions and no laparoscopy. Using an endoscopic suturing platform, the gastroenterologist places a series of full-thickness stitches along the greater curvature of the stomach, folding and cinching it into a narrow sleeve-shaped tube. The stomach becomes smaller and empties more slowly, which is what drives the weight loss — but the entire organ is still there. Nothing is stapled shut, and nothing is cut away. That single design choice is the reason ESG is reversible:

• The stitches can loosen or stretch. Sutures are not permanent welds; over time some can loosen, which is also why maintaining behavior change matters for durability.
• The stitches can be removed endoscopically. Because the sutures are placed from the inside, they can in principle be cut or removed with an endoscope, returning the stomach toward its original shape.
• The procedure can be redone or tightened. If restriction is lost, ESG can be repeated or revised without having burned any anatomical bridges.
• No tissue is missing. The full stomach remains, so the anatomy needed for a future surgical procedure is intact.

Surgery is irreversible: the sharp contrast

To see why ESG's reversibility matters, put it next to what surgery actually does. Surgical sleeve gastrectomy permanently removes 70–80% of the stomach — that tissue is excised and discarded, and it cannot be restored. Roux-en-Y gastric bypass permanently reroutes the stomach and small intestine. Both are more powerful than ESG (~25–30% TBWL in randomized trials such as SLEEVEPASS^[5], versus ~13.6–16% for ESG^[1][3]), but that power comes with permanence:

The practical upshot is about optionality. If you have an ESG and later decide you need more weight loss, a surgical sleeve or bypass is still on the table — ESG did not consume any of that tissue. If you have a sleeve gastrectomy and want to reverse course, you cannot get the removed stomach back. This is why ESG is often framed as the option that “keeps every door open.”

How ESG's reversibility compares to a GLP-1

A GLP-1 like Wegovy or Zepbound is “reversible” in a completely different sense: you can simply stop the weekly injection. But there is a catch — when you stop a GLP-1, the appetite suppression stops with it, and the weight loss tends to reverse. So a GLP-1 is easy to discontinue precisely because it is a drug that works only while you take it. ESG is the mirror image:

• A GLP-1's effect is contingent on continued dosing. Reversible to stop, but the benefit reverses too. STEP-1 showed ~14.9% TBWL with semaglutide^[6] and SURMOUNT-1 ~20.9% with tirzepatide^[7] — while on the drug.
• ESG's effect persists while the sutures hold. You are not taking anything daily or weekly; the restriction is mechanical and durable to about five years^[3]. Reversing it is an active choice (removing sutures), not what happens by default.
• They can be combined. Because ESG is reversible and additive rather than destructive, it layers cleanly with a GLP-1 — ESG plus liraglutide outperformed ESG alone in a randomized trial^[4], a “procedure plus medication” strategy.

Prefer a reversible GLP-1 to a procedure? Top vetted providers

What reversibility does — and doesn't — change for you

• It lowers the stakes of the decision. Choosing ESG is a less irreversible commitment than choosing surgery, which is reassuring for people not ready to permanently alter their anatomy.
• It preserves your surgical bridge. If ESG under-delivers for you, a surgical sleeve or bypass is still fully available — you have not lost that option^[5].
• It does not mean the weight loss is fragile. Reversibility and durability coexist: ESG holds near 16% at five years while intact^[3]. Do not mistake “reversible” for “won't last.”
• It does not remove the need for behavior change. Sutures can loosen, and regain is possible without sustained habits; ESG restricts the stomach, it does not do the eating for you. That is why some people pair it with a GLP-1^[4].
• It does not make ESG risk-free. It is still an invasive endoscopic procedure under sedation, with serious adverse events around 2%^[2] — reversibility is about anatomy, not about zero risk.

Bottom line

• Yes, ESG is generally reversible — it places sutures rather than removing stomach tissue, so the stitches can be removed or revised, the procedure can be redone, and future surgery stays fully available.
• Surgery is not reversible: a sleeve gastrectomy permanently removes 70–80% of the stomach^[5]. That is the sharp contrast and the core reason people value ESG's flexibility.
• Reversible is not temporary. While the sutures hold, ESG's weight loss is durable — 13.6% at one year^[1] and near 16% at five years^[3].
• Reversibility differs from a GLP-1's. A GLP-1 is easy to stop but its weight loss reverses too; ESG's effect persists by default and reversing it is an active choice.
• Flexibility still requires the fundamentals: behavior change protects the result, ESG can be combined with a GLP-1^[4], and it remains an invasive procedure with a real (~2%) serious-complication rate^[2].

Related research

• Endoscopic sleeve gastroplasty (ESG): the full evidence — the cornerstone on efficacy, safety, durability, and how ESG compares to GLP-1s and surgery
• How much does ESG cost, and is it worth it? — the one-time price vs an ongoing GLP-1 bill, and why insurance usually says no
• ESG vs gastric sleeve — the reversible incisionless procedure vs the permanent surgical sleeve
• ESG results and before-and-after — what the durable weight-loss trajectory looks like
• ESG vs GLP-1 (semaglutide and tirzepatide) — the focused procedure-vs-drug comparison
• Gastric balloon for weight loss — the truly temporary 6-month device, for contrast
• Gastric balloon cost — the other endoscopic option's price picture
• Endoscopic weight-loss options: the overview — the pillar map of ESG, the balloon, GLP-1s, and surgery
• How much is weight-loss surgery? — the cost of the permanent surgical options
• Does insurance cover weight-loss surgery? — why ESG is usually out of pocket while surgery often isn't
• Bariatric surgery vs GLP-1s — the full drugs-vs-surgery weight-loss, cost, and outcomes comparison

Important disclaimer. This article is educational and does not constitute medical advice. Endoscopic sleeve gastroplasty is an invasive procedure with real risks; whether it is appropriate or reversible in your specific case depends on your anatomy, health, and goals, and must be assessed by a qualified bariatric endoscopist or obesity-medicine physician. “Reversible” describes the general nature of a suture-based procedure and does not guarantee that reversal is simple, complete, or advisable for any individual. Cross-trial comparisons with GLP-1 drugs and with surgery are not head-to-head and should be interpreted with care. Any cost figures are current US market ranges, not trial-derived numbers. Do not start, stop, or change any treatment based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-07-01.

Last verified: 2026-07-01. Next review: every 12 months, or sooner if a major long-term ESG durability or suture-revision study is published.